Tatva Chintan Pharma Chem Limited
Commodities›Chemicals›Chemicals & Petrochemicals›Specialty Chemicals
Key metrics
Price as of 2026-07-17
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 114 Cr | 211 Cr | 295 Cr | 394 Cr | 105 Cr | 189 Cr | 86 Cr | 108 Cr | 117 Cr | 124 Cr | 131 Cr | 134 Cr |
| Operating expenses (approx.) | 92 Cr | 168 Cr | 240 Cr | 318 Cr | 92 Cr | 169 Cr | 79 Cr | 98 Cr | 98 Cr | 100 Cr | 104 Cr | 106 Cr |
| EBITDA | 22 Cr | 43 Cr | 56 Cr | 76 Cr | 14 Cr | 20 Cr | 7 Cr | 10 Cr | 18 Cr | 23 Cr | 27 Cr | 28 Cr |
| OPM % | 19.5% | 20.5% | 18.8% | 19.2% | 13.1% | 10.5% | 8.3% | 9.0% | 15.8% | 18.8% | 20.7% | 20.7% |
| Other income | 1 Cr | 2 Cr | 3 Cr | 8 Cr | 1 Cr | 2 Cr | 0.04 Cr | 0.72 Cr | 1 Cr | 1 Cr | 2 Cr | -0.35 Cr |
| Interest | 3 Cr | 6 Cr | 6 Cr | 7 Cr | 0.31 Cr | 0.49 Cr | 0.42 Cr | 0.39 Cr | 0.41 Cr | 0.51 Cr | 0.49 Cr | 1 Cr |
| Depreciation | 6 Cr | 13 Cr | 19 Cr | 26 Cr | 7 Cr | 13 Cr | 7 Cr | 7 Cr | 9 Cr | 9 Cr | 9 Cr | 10 Cr |
| Profit before tax | 13 Cr | 25 Cr | 30 Cr | 44 Cr | 7 Cr | 6 Cr | -0.23 Cr | 2 Cr | 9 Cr | 14 Cr | 18 Cr | 17 Cr |
| Tax % | 29.2% | 29.8% | 30.6% | 30.3% | 23.5% | 21.5% | 158.7% | 49.2% | 26.9% | 27.4% | 14.1% | 37.8% |
| Net profit | 10 Cr | 17 Cr | 21 Cr | 30 Cr | 5 Cr | 5 Cr | 0.14 Cr | 1 Cr | 7 Cr | 10 Cr | 15 Cr | 10 Cr |
| EPS (₹) | ₹4.29 | ₹7.72 | ₹9.13 | ₹13.26 | ₹2.23 | ₹1.94 | ₹0.06 | ₹0.44 | ₹2.84 | ₹4.24 | ₹6.49 | ₹4.41 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| Sales | 434 Cr | 424 Cr | 394 Cr | 383 Cr | 506 Cr | Sign in for TTM |
| Operating expenses (approx.) | 317 Cr | 367 Cr | 325 Cr | 346 Cr | 409 Cr | Sign in for TTM |
| EBITDA | 117 Cr | 57 Cr | 68 Cr | 37 Cr | 97 Cr | Sign in for TTM |
| OPM % | 27.0% | 13.5% | 17.3% | 9.5% | 19.1% | Sign in for TTM |
| Other income | 9 Cr | 6 Cr | 8 Cr | 2 Cr | 4 Cr | Sign in for TTM |
| Interest | 5 Cr | 8 Cr | 7 Cr | 1 Cr | 3 Cr | Sign in for TTM |
| Depreciation | 8 Cr | 10 Cr | 26 Cr | 28 Cr | 37 Cr | Sign in for TTM |
| Profit before tax | 104 Cr | 45 Cr | 44 Cr | 8 Cr | 57 Cr | Sign in for TTM |
| Tax % | 7.9% | -1.6% | 30.3% | 24.6% | 26.2% | Sign in for TTM |
| Net profit | 96 Cr | 45 Cr | 30 Cr | 6 Cr | 42 Cr | Sign in for TTM |
| EPS (₹) | ₹44.59 | ₹20.52 | ₹13.26 | ₹2.44 | ₹17.98 | Sign in for TTM |
| Dividend payout % | 0.0% | 9.7% | 15.4% | 81.9% | 5.6% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 22 Cr | 22 Cr | 23 Cr | 23 Cr | 23 Cr |
| Reserves | 451 Cr | 493 Cr | 714 Cr | 715 Cr | 758 Cr |
| Borrowings | 120 Cr | 170 Cr | 14 Cr | 36 Cr | 115 Cr |
| Other liabilities | 63 Cr | 71 Cr | 67 Cr | 61 Cr | 107 Cr |
| Total liabilities | 652 Cr | 756 Cr | 819 Cr | 836 Cr | 1,004 Cr |
| Fixed assets (net) | 159 Cr | 196 Cr | 427 Cr | 526 Cr | 604 Cr |
| CWIP | 51 Cr | 231 Cr | 73 Cr | 22 Cr | 23 Cr |
| Investments | 0.67 Cr | 0.0000 Cr | 10 Cr | 0.0000 Cr | 4 Cr |
| Other assets | 429 Cr | 314 Cr | 298 Cr | 265 Cr | 350 Cr |
| Total assets | 652 Cr | 756 Cr | 819 Cr | 836 Cr | 1,004 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operating activity | 20 Cr | 28 Cr | 98 Cr | 25 Cr | 31 Cr |
| Cash from investing | -197 Cr | -101 Cr | -121 Cr | -65 Cr | -116 Cr |
| Cash from financing | 235 Cr | 38 Cr | 31 Cr | 17 Cr | 79 Cr |
| Net cash flow | 59 Cr | -36 Cr | 8 Cr | -24 Cr | -6 Cr |
| Free cash flow (OCF − Capex) | -69 Cr | -175 Cr | -30 Cr | -52 Cr | -82 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROCE % | 23.0% | 6.9% | 5.7% | 1.1% | 6.7% |
| ROE % | 20.3% | 8.8% | 4.1% | 0.8% | 5.4% |
| Debtor days | 52 | 73 | 65 | — | — |
| Inventory days | 230 | 274 | 312 | 281 | 272 |
| Days payable | 63 | 54 | 92 | — | — |
| Cash conversion cycle | 219 | 292 | 285 | 281 | 272 |
| Debt / equity | 0.26 | 0.33 | 0.02 | 0.05 | 0.15 |
| Current ratio | 2.53 | 1.33 | 3.74 | 2.76 | 1.64 |
| Net debt / EBITDA | 0.00 | 2.51 | -0.31 | 0.68 | 1.13 |
Compare with peers
Loading peers…